Hypoxia inducible factor 1-α expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer

To investigate the impact on survival of HIF 1-α expression on primary advanced epithelial ovarian cancer (EOC), we examined the correlations between prognosis and HIF 1-α expression by Western blot analysis in 52 cases of stage III/IV EOC. HIF 1-α expression was confirmed in 36 cases (69.2%) of EOC, and HIF 1-α-expressing tumors had a significantly higher rate of response (p < 0.01) to postoperative paclitaxel/carboplatin combination chemotherapy (TC) than tumors without HIF1-α expression. Moreover, patients with HIF 1-α-expressing tumors with suboptimal resection of stage III/IV tumors indicated for postoperative TC exhibited significantly better survival (p < 0.01).